Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

 

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge, CB2 0AA

United Kingdom

T: [phone]

 

astrazeneca.com

 

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

February 20, 2024

 

Re:            Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

 

Ladies and Gentlemen,

 

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that AstraZeneca PLC has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on February 20, 2024. The disclosure can be found under the heading “Item 4.B Business Overview—Disclosures Under the Iran Threat Reduction and Syria Human Rights Act of 2012” in the Annual Report on Form 20-F.

 

 

 

 

Respectfully submitted,

 

/s/ Adrian Kemp
Adrian Kemp
Company Secretary
AstraZeneca PLC

 

AstraZeneca PLC

Registered in England No. 2723534

Registered office: 1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge, CB2 0AA

United Kingdom

 

 

 

 

 

---